A method to reduce the influence of lipemia on transscattering fusion-enhanced immunoturbidimetric detection

Abstract

This invention discloses a method for reducing the influence of lipemia on transmission-scattering fusion-enhanced immunoturbidimetric assays, specifically including the following steps: S1, measuring the average absorbance signal value of a specific measurement point after adding reaction buffer to each sample; S2, measuring the non-lipemia turbidity value of different samples that does not cause a low scattering measurement after adding reaction buffer, i.e., the background; S3, comparing the value measured in step S1 with the value measured in step S2 to determine whether the scattering turbidity measurement results need to be revised; This invention relates to the field of transmission-scattering fusion-enhanced immunoturbidimetric assay technology. This method for reducing the influence of lipemia on transmission-scattering fusion-enhanced immunoturbidimetric assays achieves this by demonstrating a strong correlation between the turbidity of lipid particles in lipemia samples and the transmission turbidity signal value in the reaction buffer during transmission-scattering fusion-enhanced immunoturbidimetric assays, and by quantifying this correlation through the transmission absorbance values ​​of the sample and R1.

Description

Technical Field

[0001] This invention relates to the field of transmission scattering fusion enhanced immunoturbidimetric detection technology, specifically a method for reducing the influence of lipemia on transmission scattering fusion enhanced immunoturbidimetric detection. Background Technology

[0002] Transmission-scattering fusion-enhanced immunoturbidimetric assay is a new methodology that emerged in 2020 and is an upgrade from the original latex immunoturbidimetric assay. The implementation of this methodology requires both hardware and reagent foundations.

[0003] Transmissive-scattering fusion-enhanced immunoturbidimetric assays typically consist of a reaction buffer (labeled R1), a sensitized latex solution labeled with the target antibody or antigen (labeled R2), a calibrator of known concentration, and quality controls. The scattering detection in transmissive-scattering fusion-enhanced immunoturbidimetric assays inherits all the advantages and disadvantages of traditional scattering immunoturbidimetric assays. In particular, the strong influence of lipemia on scattering immunoturbidimetry is also inherited by transmissive-scattering fusion-enhanced immunoturbidimetric assays. Transmissive-scattering fusion-enhanced assays utilize scattering results in low-concentration regions, thus being strongly affected by lipemia. Commercially available scattering turbidimetric assays, from the Siemens BN series in the 1980s to the Beckman IMMAGE 800 in 2006, have yet to completely eliminate the influence of lipemia; their effects can only be mitigated through methods such as sample dilution.

[0004] The reason for this is that automated turbidimetric assays are typically performed in reaction cuvettes, resulting in a certain "thickness" of the solution. Since turbidimetric analysis detects the intensity of scattered light, the scattered light generated by particles (such as antigen-antibody immune complexes) in the solution near the emission source (front end) is blocked by other particles near the detector (back end), preventing it from reaching the detector and thus reducing the scattered light signal value. Therefore, turbidimetric assays usually need to be performed in a relatively "dilute" solution, where the scattered light generated by the immune complexes at the front end is not blocked, or is blocked as little as possible, by particles at the back end. The influence of lipemia mainly comes from the fat particles in lipemia, which make the particle concentration in the test solution "thick," preventing the scattered light signal value generated by the immunoturbidimetric reaction from reaching the detector smoothly, thus reducing the signal value and underestimating the detection result.

[0005] Traditional turbidimetric assays, while reducing the influence of "thick" particulate matter by dilution, often result in an overly dilute reaction solution, making antigen-antibody immune responses difficult to occur, especially for assays with low analyte concentrations (below 1000 ug / L). In such cases, increasing sample volume to improve sensitivity is often necessary, making dilution impractical. Furthermore, the "thickness" of lipemia varies among samples, with thicker samples exhibiting a more severe impact. Automated equipment cannot perform customized testing with individual dilutions for each sample; it must perform batch operations with uniform dilutions. Therefore, traditional automated turbidimetric assays still cannot solve the problem of lipemia's influence. To address this, this invention provides a method to reduce the influence of lipemia on transmissive scattering fusion enhanced immunoturbidimetric assays, resolving these issues. Summary of the Invention

[0006] (a) Technical problems to be solved

[0007] To address the shortcomings of existing technologies, this invention provides a method for reducing the influence of lipemia on transmissivity-to-scat fusion enhanced immunoturbidimetric detection, thus solving the problems mentioned in the background section.

[0008] (II) Technical Solution

[0009] To achieve the above objectives, the present invention provides the following technical solution: a method for reducing the influence of lipemia on transmissivity-to-spheric scattering fusion-enhanced immunoturbidimetric detection, specifically comprising the following steps:

[0010] S1. Measure the average absorbance signal value of a specific section of the photometric point after adding reaction buffer to each sample;

[0011] S2. Measure the non-lipemic turbidity values ​​of different samples that do not show a low scattering reading after adding the reaction buffer, i.e., the background;

[0012] S3. Compare the values ​​measured in step S1 with the values ​​measured in step S2 to determine whether the scattering turbidimetric measurement results need to be revised.

[0013] Preferably, the value measured in step S1 is expressed as R1a, and the value measured in step S2 is expressed as R1b.

[0014] Preferably, the determination formula for the scattering turbidimetric measurement result in step S3 is: scattering revision value = initial scattering measurement value + initial scattering measurement value * (LN value) * correction coefficient k, where, LN value = output value of the selective function IF((R1a-R1b)>0, (R1a-R1b), 0).

[0015] Preferably, the method for determining whether the initial scattering measurement value in step S3 needs to be corrected is as follows: when R1a is greater than R1b, LN = R1a - R1b, that is, when there is substantial lipemia turbidity, the scattering turbidimetric measurement result is corrected; when the sample is not actually lipemia, or the particulate matter of lipemia is insufficient to cause the scattering measurement result to be low, and only other factors cause R1a to have a non-zero value, then R1a is less than or equal to R1b, the output result is 0, and the scattering turbidimetric measurement result is not corrected.

[0016] Preferably, the LN value ranges from 0 to LNH (the upper limit of LN).

[0017] Preferably, the revision value is considered valid when it is within ±15% of the transmission result in the transmission-scattering fusion region.

[0018] Preferably, the transmission-scattering fusion region is a section where both scattering and transmission can output results normally, that is, the overlapping area between the lower limit of the transmission technology limit value and the upper limit of the scattering technology limit value.

[0019] (III) Beneficial Effects

[0020] This invention provides a method for reducing the influence of lipemia on transmissivity-to-saturation fusion-enhanced immunoturbidimetric assays. Compared with existing technologies, it has the following advantages:

[0021] (1) The method to reduce the influence of lipemia on transmissive scattering fusion enhanced immunoturbidimetric detection is based on the strong correlation between the turbidity of fat particles (non-triglyceride or cholesterol concentration) in lipemia samples and the transmission turbidity signal value in reagent R1 (reaction buffer) added to the sample during transmissive scattering fusion enhanced immunoturbidimetric detection. The correlation is further quantified by the transmission absorbance values ​​of the sample and R1.

[0022] (2) The method to reduce the influence of lipemia on transmissivity-to-scattering fusion-enhanced immunoturbidimetric assays utilizes the principle that lipemia lipid particles increase the "consistency" of the reaction solution, thus hindering scattered light from reaching the photodetector. It can be inferred that the lipemia R1 transmissivity turbidity (LN) is positively correlated with "consistency" within a certain range, and that LN has a functional relationship with the underestimation of the scattering measurement result within that range. Through a large-scale study of lipemia samples, it was determined that LN, within a certain range, is strongly correlated with the extent to which the scattering measurement result output by the transmissivity-to-scattering fusion-enhanced assay is lower than the transmission result. Simultaneously, using the functional relationship between LN and the underestimation of the scattering measurement result, a certain functional relationship (formula) is used to correct the lipemia scattering measurement result. Furthermore, by introducing this correction formula into the transmissivity-to-scattering integrated analyzer software system or the LIS system for patient result output, the final output result can be corrected, thereby enhancing the reliability of the output result. Attached Figure Description

[0023] Figure 1 This is a graph showing the relationship between wavelength and R1b for a method of the present invention that reduces the influence of lipid blood on transmission scattering fusion and enhances immunoturbidimetric detection;

[0024] Figure 2 The present invention provides a method for reducing the influence of lipid blood on transmission scattering fusion and enhancing immunoturbidimetric detection, and provides a relationship diagram between wavelength and LNH. Detailed Implementation

[0025] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0026] The embodiments of the present invention provide the following technical solutions:

[0027] I. Formula Verification:

[0028] On a Hitachi 3500 transmission and scattering analyzer, for the ferritin (FER) test, with an 8µl sample yielding 160µl R1 and 80µl R2 (i.e., sample volume / R1 = 1 / 20), and a transmission technique limit of 30ng / ml and a scattering technique limit of 450ng / ml (i.e., the transmission-scattering fusion region is 30-450ng / ml), the method was validated at transmission wavelengths of 570nm, 660nm, and 800nm. After calibration using the same calibrators, lipemic, hemolytic, and jaundiced samples were measured, and the differences between the revised scattering results and the transmission results were compared. For samples with transmission results between 0-30ng / ml, due to the large fluctuations in transmission results, the scattering results were directly corrected and not compared with the transmission results. For samples with initial transmission results between 30-450ng / ml, the above formula was used for correction, and the corrected results were compared with the transmission results to verify the reliability of the formula. For samples with transmission results greater than 450ng / ml, the transmission results were reported directly without correction.

[0029] Correct formula parameters:

[0030] Scattering revision value = initial scattering measurement value + initial scattering measurement value * (LN) * correction factor k;

[0031] At 570nm, R1b=700, k=0.00012; LN=IF((R1a-700)>0,(R1a-700),0);

[0032] At 660nm, R1b=400, k=0.00017; LN=IF((R1a-400)>0,(R1a-400),0);

[0033] At 800nm, R1b = 150, k = 0.00025; LN = IF((R1a-150)>0, (R1a-150), 0).

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040] Lipid sample 2 was used up after testing at 570nm, and the 660nm and 800nm ​​tests were not completed, so it is not included in the statistics. It can be seen that for some samples with LN greater than 2000, the bias correction effect was not good. Samples with LN less than 10000 were diluted 1 / 5 and retested. Extremely severe lipemia sample 45 was diluted 8 times and retested. The data are as follows:

[0041]

[0042]

[0043] As can be seen, at a transmission wavelength of 570 nm, the revised method performs well for samples in the transmission-scattering fusion region, has no effect on the measurement of non-lipemic samples, and after revision, the bias of all lipemic samples is reduced to less than 10%.

[0044]

[0045]

[0046]

[0047]

[0048]

[0049]

[0050] Lipid sample 2 was used up after testing at 570nm, and the 660nm and 800nm ​​tests were not completed, so it is not included in the statistics. It can be seen that at 660nm, the bias correction effect was not good for some samples with LN greater than 1500. Samples with LN less than 7500 were diluted by 1 / 5 and retested. Extremely severe lipemia sample 45 was diluted 8 times and retested. The data are as follows:

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

[0057] Blood sample 2 was used up after testing at 570nm, and the 660nm and 800nm ​​tests were not completed and therefore not included in the statistics. It can be seen that at 800nm, the bias correction effect was not good for some samples with an LN greater than 800. Samples with an LN less than 4000 were diluted 1 / 5 and retested. Extremely severe lipemia sample 45 was diluted 9 times and retested. The data are as follows:

[0058]

[0059]

[0060] As can be seen, at a transmission wavelength of 660 nm, the revised method performs well for samples in the transmission-scattering fusion region, has no effect on the measurement of non-lipemic samples, and after revision, the bias of all lipemic samples is reduced to less than 10%.

[0061]

[0062]

[0063] As can be seen, at a transmission wavelength of 800 nm, the revised method performs well for samples in the transmission-scattering fusion region, has no effect on the measurement of non-lipemic samples, and after revision, the bias of all lipemic samples is reduced to less than 10%.

[0064] II. Verification of the range of parameter k:

[0065] We selected 570nm data to show the influence of the lower limit of the k value, and selected 800nm ​​data to show the influence of the upper limit of the k value.

[0066] A lower k value results in a smaller revised value and a greater negative bias; an increased k value results in a larger revised value and a greater positive bias. An appropriate k value ensures that the bias of as many samples as possible is within 15% or even 10%, minimizing the number of samples that need to be diluted and retested.

[0067] Scattering revision value = initial scattering measurement value + initial scattering measurement value * (LN) * correction factor k;

[0068] At 570nm, R1b = 700, k = 0.00007; LN = IF((R1a-700)>0, (R1a-700), 0);

[0069] At 800nm, R1b = 150, k = 0.00028; LN = IF((R1a-150)>0, (R1a-150), 0).

[0070]

[0071]

[0072]

[0073]

[0074] As can be seen, at 570nm, R1b=700, k=0.00007; when LN=IF((R1a-700)>0,(R1a-700),0), there are 2 samples (lipemic sample 60 and lipemic sample 18) in the 0-LNH region with a deviation exceeding -10%, and many samples are on the edge of -10%, so the revision result is not ideal.

[0075]

[0076]

[0077]

[0078]

[0079]

[0080] As can be seen, at 800nm, R1b=150, k=0.00028; when LN=IF((R1a-150)>0,(R1a-150),0), although some samples with large negative biases in the 0-LNH region showed improvement, two samples (lipemia sample 59 and lipemia sample 19) had biases exceeding 10%, and many samples were on the edge of 10%, so the revision results were not ideal.

[0081] Therefore, within the commonly used latex turbidity wavelength range of 570-800nm, the optimal k value is in the range of 0.0008-0.00027, following the principle of negative wavelength correlation.

[0082] III. General demonstrations of other projects:

[0083] The process of establishing a formula to reduce the effects of lipemia suitable for this project was demonstrated on a Hitachi 3500 transmission and scattering system for the procalcitonin PCT project, with a 15ul sample, 150ul R1, and 75ul R2 (i.e., 1 / 10 of the sample volume / R1 volume), a transmission wavelength of 700nm, a scattering angle of 20 degrees, and 18-34 reading points.

[0084] PCT project transmittance-scattering fusion zone: The upper limit of the scattering technology limit is 2000 pg / ml, and the lower limit of the transmission technology limit is 300 pg / ml. The range of 300-2000 pg / ml is the transmittance-scattering fusion zone. For values ​​less than 300 pg / ml, the transmission results are unreliable. The scattering results are reported, and the formula is revised, but they are not compared with the transmission results. For values ​​greater than 2000 pg / ml, the transmission results are reported, but they are not involved in the formula revision.

[0085] Template formula: Scattering revision value = Initial scattering measurement value + Initial scattering measurement value * (LN) * Correction factor k;

[0086] First, based on the "template formula," the closest initial recommended R1b value of 400 and k value of 0.00017 for 660nm were substituted into the 700nm transmission wavelength to establish a preliminary revised formula for the scattering output results. This formula was then applied to the measurement results of at least 25 lipemia samples (selected from previous lipemia samples in the range of 300-2000 pg / ml) and compared with the results of 25 other non-lipemia samples. Considering that the PCT test result of 300-2000 pg / ml requires inflammatory samples, 15 inflammatory samples and 10 ordinary samples were selected. After the above measurements, the formula was revised, and the revised deviation was compared with the initial deviation to check the reliability of the initial R1b and k values.

[0087]

[0088]

[0089]

[0090] As can be seen, at 700nm and a sample size / R1 ratio of 1 / 10, the R1a value is generally high, consistent with the principle that the R1a value is positively correlated with the sample size / R1 ratio. Meanwhile, by incorporating the R1b and k values ​​from 660nm, the bias is significantly improved after revision, but the negative bias is still relatively large. Further parameter refinement is needed: based on the principle that k is positively correlated with wavelength, the k value is increased to k = 0.00020; after testing jaundice and hemolytic samples, an R1b value of 500 is estimated to be optimal.

[0091] R1a value Sample number 109.5 Jaundice Sample 1 103.5 Jaundice sample 10 154.5 Jaundice Sample 2 64.5 Jaundice Sample 3 58.5 Jaundice Sample 4 81 Jaundice sample 5 48 Jaundice sample 6 67.5 Jaundice sample 7 58.5 Jaundice sample 8 73.5 Jaundice sample 9 114 Hemolytic sample 1 142.5 Hemolyzed sample 2 138 Hemolyzed sample 3 582 Hemolyzed sample 4 88.5 Hemolyzed sample 5

[0092]

[0093]

[0094]

[0095] As can be seen, samples with LN greater than 1300 have a large bias. They are diluted 5 times, and the measurement results after dilution are multiplied by the dilution factor.

[0096]

[0097] As can be seen from the PCT project, through parameter refinement and optimization, at 700nm, a 1 / 10 sample size / R1 ratio, R1 b=500, k=0.00020, and LN greater than 1300, a 1 / 5 dilution retest yields very good results. The deviation of all revised samples is less than 10%.

[0098] Then, more than 40 random samples were tested to ensure that at least 20 samples were in the transmittance-scattering fusion region (i.e., 300-2000 pg / ml). The parameters were 1 / 5 dilution and retesting at 700 nm, 1 / 10 sample amount / R1 amount ratio, R1b=500, k=0.00020, and LN>1300.

[0099] Template formula: Scattering revision value = Initial scattering measurement value + Initial scattering measurement value * (LN) * Correction factor k;

[0100] The verification was performed, and the results are as follows:

[0101]

[0102]

[0103]

[0104]

[0105] Please see Figures 1-2A method for reducing the influence of lipemia on transmissivity-enhanced immunoturbidimetric assays includes the following steps:

[0106] S1. Measure the average absorbance signal value of a specific section of the photometric point after adding reaction buffer R1 to each sample, i.e., R1a;

[0107] S2. Measure the non-lipemic turbidity value (i.e. "background") of each sample after adding reaction buffer R1 without causing scattering measurement to be low. This is R1b, such as the absorbance signal value of the sample when R1 is added due to sample color, bilirubin, hemolysis, etc. This value comes from the data summary. The specific values ​​are different for different parameters such as transmission wavelength and sample amount / R1 amount ratio.

[0108] S3. Compare the values ​​measured in step S1 with the values ​​measured in step S2 to determine whether the scattering turbidimetric measurement results need to be revised.

[0109] In this embodiment of the invention, the formula for determining the scattering turbidimetric measurement result in step S3 is: Scattering revision value = Initial scattering measurement value + Initial scattering measurement value * (LN value) * Correction coefficient k, where LN value = Output value of the selectivity function IF((R1a-R1b)>0, (R1a-R1b), 0). Samples below the lower limit of the transmission technology threshold but within the scattering measurement range, i.e., the segment directly outputting the scattering result, cannot be compared with the transmission result and are considered valid by default, and are directly revised according to this formula.

[0110] In this embodiment of the invention, the method for determining whether the initial scattering measurement value in step S3 needs correction is as follows: when R1a is greater than R1b, LN = R1a - R1b, that is, when there is substantial lipemia turbidity, the scattering turbidimetric measurement result is corrected; when the sample is not actually lipemia, or the particulate matter of lipemia is insufficient to cause the scattering measurement result to be low, and only other factors cause R1a to have a non-zero value, then R1a is less than or equal to R1b, the output result is 0, and the scattering turbidimetric measurement result is not corrected. The relatively reliable R1b value for the corresponding item can be obtained by accumulating a certain amount of data (such as testing a certain amount of hemolyzed, jaundice-colored samples, or turbid samples from other causes) according to the following method. It is negatively correlated with wavelength and positively correlated with the sample size / R1 ratio. For example, at the most common sample size / R1 ratio of 1 / 20, the recommended R1b value is 700 at a transmission wavelength of 570nm; 400 at a wavelength of 660nm; and 150 at a wavelength of 800nm. Those skilled in the art should follow the following method when changing the wavelength or sample size / R1 ratio: At the same wavelength, the R1b value is directly proportional to the sample size / R1 ratio. For example, at 660nm, with a 1 / 20 ratio, the R1b value is 400; with a 1 / 10 ratio, the R1b value = (1 / 10) / (1 / 20)*400 = 800; the same applies to other wavelengths. When using different wavelengths, a curve should be established with the wavelength as the X-axis and the recommended R1b value as the Y-axis. Based on the wavelength, an initial R1b value should be selected for adjustment using the three methods described above. Within the recommended R1b value ±300, the most suitable R1b value for the project should be adjusted. As described in the three methods above, at 700nm and a 1 / 10 ratio, R1b = 500 was selected for the second adjustment step, yielding better results.

[0111] In this embodiment of the invention, the LN value range is 0-LNH (the upper limit of LN). This value varies with different transmission wavelengths and is negatively correlated with wavelength. At a transmission wavelength of 570nm, the preferred LN range is 0-2000; at 660nm, the preferred LN range is 0-1500; at 800nm, the preferred LN range is 0-800. When the value exceeds the upper limit of this range, the computer software can indicate that the value is out of range, reminding the operator to dilute the sample to within the range for retesting. Preferably, the dilution ratio is 1 / 5 (i.e., when LN>LNH, the sample is diluted 5 times for testing, and the reported result is the diluted test result multiplied by the dilution factor 5). Only in extremely rare cases of very high lipemia, such as LN values ​​greater than 4000 at 800nm ​​wavelength, is it necessary to increase the dilution factor so that the diluted LN value is less than 800 before testing. The calculation method is also the same: reported result = diluted test result * dilution factor. The LNH value is negatively correlated with wavelength. A curve is established with wavelength as the X-axis and LNH value as the Y-axis, as shown below. Figure 2For different wavelengths, select the optimal LNH value within ±20% of the recommended value based on actual modified data. As mentioned in section three above, for a wavelength of 700nm, select LNH = 1300.

[0112] Here, the coefficient k is a specific functional relationship between LN and the magnitude of the lower scattering measurement value. This value varies for different items and different parameters, such as transmission wavelength. A relatively reliable k value for the corresponding item can be obtained through data accumulation and adjustment using the method described above. Preferably, in the commonly used wavelength range of 570-800nm ​​for latex turbidity, the k value is usually between 0.00008 and 0.00028. The k value is positively correlated with the wavelength. Preferably, the k value for a transmission wavelength of 570nm is 0.00012±0.00003; for 660nm, the k value is 0.00017±0.00003; and for 800nm, the recommended k value is 0.00025±0.00003.

[0113] In this embodiment of the invention, the revision result is valid when the scattering revision value is within ±15% of the transmission result in the scattering fusion region.

[0114] In this embodiment of the invention, the transmission-scattering fusion region is the section where both scattering and transmission can output results normally, that is, the overlapping area between the lower limit of the transmission technology limit value and the upper limit of the scattering technology limit value.

[0115] Furthermore, any content not described in detail in this specification is existing technology known to those skilled in the art.

[0116] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article, or apparatus.

[0117] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A method for reducing the influence of lipids on transmissivity-to-spheric scattering fusion-enhanced immunoturbidimetric detection, characterized in that, Specifically, the following steps are included: S1. Measure the average transmittance absorbance signal value of a specific section of the photometric point after adding reaction buffer to each sample; S2. Measure the non-lipemic turbidity values ​​of different samples that do not show a low scattering reading after adding the reaction buffer, i.e., the background; S3. Compare the values ​​measured in step S1 with the values ​​measured in step S2 to determine whether the turbidity measurement results need to be revised. The value measured in step S1 is expressed as R1a, and the value measured in step S2 is expressed as R1b. The formula for determining the scattering turbidimetric measurement result in step S3 is: Scattering revision value = initial scattering measurement value + initial scattering measurement value * (LN value) * correction coefficient k, where LN value = output value of the selective function IF((R1a-R1b)>0, (R1a-R1b),0); The method for determining whether the initial scattering measurement value in step S3 needs to be corrected is as follows: when R1a is greater than R1b, LN = R1a - R1b, that is, when there is substantial lipemia turbidity, the scattering turbidimetric measurement result is corrected; when the sample is not actually lipemia, or the particulate matter of lipemia is insufficient to cause the scattering measurement result to be low, and only other factors cause R1a to have a non-zero value, then R1a is less than or equal to R1b, the output result is 0, and the scattering turbidimetric measurement result is not corrected.

2. The method for reducing the influence of lipemia on transmissivity-to-transmittance fusion enhanced immunoturbidimetric detection according to claim 1, characterized in that: The value of LN is in the range of 0-LNH, where LNH is the upper limit of LN.

3. The method for reducing the influence of lipemia on transmissivity-to-transmittance fusion enhanced immunoturbidimetric detection according to claim 1, characterized in that: The revision value is considered valid when it is within ±15% of the transmission result in the transmission-scattering fusion region.

4. The method for reducing the influence of lipemia on transmissivity-to-transmittance fusion enhanced immunoturbidimetric detection according to claim 3, characterized in that: The transmission and scattering fusion zone is the section where both scattering and transmission can output results normally, that is, the overlapping area between the lower limit of the transmission technology limit and the upper limit of the scattering technology limit.

Images